{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:50:25Z","timestamp":1794379825887,"version":"4.9.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pyoderma gangrenosum (PG) is a rare autoinflammatory ulcerative neutrophilic skin disease. Its clinical presentation is a rapidly progressing painful skin ulcer with ill-defined borders and surrounding erythema. The pathogenesis of PG is complex and not fully understood. Clinically, patients with PG often have various systemic diseases, the most common being inflammatory bowel disease (IBD) and arthritis. Due to the lack of specific biological markers, diagnosing PG remains difficult, which easily resulting in misdiagnosis. Some validated diagnostic criteria have been applied in clinical practice that facilitate its diagnosis. The treatment of PG currently consists mainly of immunosuppressive and immunomodulatory agents, especially biological agents, which have bright prospects for PG therapy. After the systemic inflammatory response is controlled, the problem of wounds becomes the main contradiction in PG treatment. Surgery is not controversial for PG, increasing evidence shows that with adequate systemic treatment, the benefits of reconstructive surgery for patients are increasing.<\/jats:p>","DOI":"10.3389\/fmed.2023.1134939","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:31:45Z","timestamp":1676374305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Practical aspects of the diagnosis and management of pyoderma gangrenosum"],"prefix":"10.3389","volume":"10","author":[{"given":"Bo","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","article-title":"Pyoderma gangrenosum: an updated review.","volume":"23","author":"Ruocco","year":"2009","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","article-title":"Etiology and management of pyoderma gangrenosum: a comprehensive review.","volume":"13","author":"Ahronowitz","year":"2012","journal-title":"Am J Clin Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/iwj.13389","article-title":"Pyoderma gangrenosum: from historical perspectives to emerging investigations.","volume":"17","author":"Hobbs","year":"2020","journal-title":"Int Wound J."},{"key":"B4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-017-8621-8","article-title":"A comprehensive review of neutrophilic diseases.","volume":"54","author":"Marzano","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1046\/j.1523-1747.1998.00311.x","article-title":"Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum.","volume":"111","author":"Adachi","year":"1998","journal-title":"J Invest Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-017-0265-1","article-title":"Papa, Pash and Papash syndromes: pathophysiology, presentation and treatment.","volume":"18","author":"Cugno","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of inflammation in neutrophil-mediated skin diseases.","volume":"10","author":"Marzano","year":"2019","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jid.2020.08.028","article-title":"Phenotypic associations of pstpip1 sequence variants in Pstpip1-associated autoinflammatory diseases.","volume":"141","author":"Boursier","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2340\/00015555-2008","article-title":"effective strategies for the management of pyoderma gangrenosum: a comprehensive review.","volume":"95","author":"Patel","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1365-2249.2010.04201.x","article-title":"Role of Inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases.","volume":"162","author":"Marzano","year":"2010","journal-title":"Clin Exp Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1111\/pde.13471","article-title":"Pyoderma gangrenosum in an infant: a case report and review of the literature.","volume":"35","author":"Crouse","year":"2018","journal-title":"Pediatr Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1111\/jdv.15730","article-title":"Age-specific characteristics of neutrophilic dermatoses and neutrophilic diseases in children.","volume":"33","author":"Bucchia","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1046\/j.1468-3083.2002.00476_12.x","article-title":"Pyoderma gangrenosum in pregnancy.","volume":"16","author":"Aytekin","year":"2002","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jdcr.2017.03.016","article-title":"Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone.","volume":"3","author":"Stiegler","year":"2017","journal-title":"JAAD Case Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study.","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2019.08.001","article-title":"Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis.","volume":"83","author":"Xu","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/wrr.13005","article-title":"Pyoderma gangrenosum study pilot registry: the first step to a better understanding.","volume":"30","author":"Orfaly","year":"2022","journal-title":"Wound Repair Regen."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1111\/1346-8138.14658","article-title":"Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey.","volume":"46","author":"Yamamoto","year":"2019","journal-title":"J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3776","article-title":"Pyoderma gangrenosum: a retrospective study of clinical charac-teristics, comorbidities, response to treatment and mortality related to prednisone dose.","volume":"101","author":"Schosler","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","article-title":"The association of age with clinical presentation and comorbidities of pyoderma gangrenosum.","volume":"154","author":"Ashchyan","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis.","volume":"19","author":"Kridin","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.20566","article-title":"Challenging the association of hepatitis c and pyoderma gangrenosum.","volume":"185","author":"Croitoru","year":"2021","journal-title":"Br J Dermatol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum.","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1093\/rheumatology\/keab194","article-title":"Pyoderma gangrenosum induced by adalimumab in a seropositive rheumatoid arthritis patient: a paradoxical effect of adalimumab?","volume":"60","author":"Tan","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev","DOI":"10.12688\/f1000research.19909.1","article-title":"Recent advances in managing and understanding pyoderma gangrenosum.","volume":"8","author":"Fletcher","year":"2019","journal-title":"F1000Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment.","volume":"18","author":"Alavi","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.25259\/IJDVL_1158_20","article-title":"Imatinib-induced pyoderma gangrenosum in a patient with chronic myeloid leukemia.","volume":"87","author":"Faraci","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/CAD.0000000000001140","article-title":"Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.","volume":"33","author":"Khoshnam-Rad","year":"2022","journal-title":"Anticancer Drugs."},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","article-title":"Drug-induced pyoderma gangrenosum: a review.","volume":"19","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts.","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16401","article-title":"The Paracelsus score: a novel diagnostic tool for pyoderma gangrenosum.","volume":"180","author":"Jockenhofer","year":"2019","journal-title":"Br J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/wrr.12780","article-title":"The utility and challenges of histopathologic evaluation in the diagnosis of nonmalignant skin ulcers.","volume":"28","author":"Hammer","year":"2020","journal-title":"Wound Repair Regen."},{"key":"B34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","article-title":"Comparison of three diagnostic frameworks for pyoderma gangrenosum.","volume":"141","author":"Haag","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/bjd.20967","article-title":"Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and Paracelsus criteria: a multicentre, retrospective cohort study.","volume":"186","author":"Min","year":"2022","journal-title":"Br J Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000518966","article-title":"International dermatology outcome measures (Ideom): report from the 2020 annual meeting.","volume":"238","author":"Kohn","year":"2022","journal-title":"Dermatology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa013383","article-title":"Skin ulcers misdiagnosed as pyoderma gangrenosum.","volume":"347","author":"Weenig","year":"2002","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2018.7445","article-title":"A case of chronic ulcer due to subcutaneous arteriolosclerosis in an obese patient mimicking pyoderma gangrenosum.","volume":"10","author":"Ficicioglu","year":"2018","journal-title":"Dermatol Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/iwj.13196","article-title":"Necrotising fasciitis or pyoderma gangrenosum: a fatal dilemma.","volume":"16","author":"Demirdover","year":"2019","journal-title":"Int Wound J."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2021.105697","article-title":"An extensive pyoderma gangrenosum mimicking necrotizing fasciitis: an unusual case report.","volume":"81","author":"Aziret","year":"2021","journal-title":"Int J Surg Case Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1111\/jdv.15585","article-title":"Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two?","volume":"33","author":"Cirotteau","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13412","article-title":"PG-time: a practical approach to the clinical management of pyoderma gangrenosum.","volume":"33","author":"Janowska","year":"2020","journal-title":"Dermatol Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00403-019-01912-1","article-title":"Extracutaneous involvement of pyoderma gangrenosum.","volume":"311","author":"Borda","year":"2019","journal-title":"Arch Dermatol Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-51","article-title":"UK dermatology clinical trials network\u2019s stop gap trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.","volume":"13","author":"Craig","year":"2012","journal-title":"Trials."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jama.284.12.1546","article-title":"Clinical features and treatment of peristomal pyoderma gangrenosum.","volume":"284","author":"Hughes","year":"2000","journal-title":"JAMA."},{"key":"B47","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/01.ASW.0000755920.76330.21","article-title":"Systematic review of depression and anxiety in adults with pyoderma gangrenosum.","volume":"34","author":"McPhie","year":"2021","journal-title":"Adv Skin Wound Care."},{"key":"B48","first-page":"151","article-title":"A comprehensive review of local pharmacologic therapy for pyoderma gangrenosum.","volume":"31","author":"Baltazar","year":"2019","journal-title":"Wounds."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/archdermatol.2010.393","article-title":"Is topical monotherapy effective for localized pyoderma gangrenosum?","volume":"147","author":"Le Cleach","year":"2011","journal-title":"Arch Dermatol."},{"key":"B50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.1956.01550110087017","article-title":"Pyoderma gangrenosum; report of a case controlled by cortisone.","volume":"74","author":"Greco","year":"1956","journal-title":"AMA Arch Dermatol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the stop gap randomised controlled trial.","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/bjd.14619","article-title":"Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients.","volume":"175","author":"Herberger","year":"2016","journal-title":"Br J Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/ijd.12519","article-title":"Malignant pyoderma gangrenosum eroding the parotid gland successfully treated with dexamethasone pulse therapy.","volume":"53","author":"Ambooken","year":"2014","journal-title":"Int J Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/09546634.2014.883061","article-title":"Gulliver\u2019s sign: a recognizable transition from inflammatory to healing stages of pyoderma gangrenosum.","volume":"26","author":"Landis","year":"2015","journal-title":"J Dermatolog Treat."},{"key":"B55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjd.19027","article-title":"Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review.","volume":"183","author":"Lu","year":"2020","journal-title":"Br J Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/17512433.2020.1709825","article-title":"Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum.","volume":"13","author":"Goldust","year":"2020","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others.","volume":"53","author":"Puig","year":"2018","journal-title":"Curr Probl Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.15850","article-title":"Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series.","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1534734620940459","article-title":"Applying intravenous immunoglobulin and negative-pressure wound therapy to treat refractory pyoderma gangrenosum: a case report.","volume":"20","author":"Jin","year":"2021","journal-title":"Int J Low Extrem Wounds."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14322","article-title":"Refractory steroid-resistant pyoderma gangrenosum successfully treated with intravenous immunoglobulins.","volume":"33","author":"Kapetanovic","year":"2020","journal-title":"Dermatol Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaad.2021.09.053","article-title":"Wound care dressings for pyoderma gangrenosum.","volume":"86","author":"Strunck","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-med-052716-030320","article-title":"New molecular diagnostic approaches to bacterial infections and antibacterial resistance.","volume":"69","author":"Tsalik","year":"2018","journal-title":"Annu Rev Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/s0966-842x(02)02438-1","article-title":"Molecular detection and genotyping of pathogens: more accurate and rapid answers.","volume":"10","author":"Versalovic","year":"2002","journal-title":"Trends Microbiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients.","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jaad.2010.01.049","article-title":"Clinical features of pyoderma gangrenosum and current diagnostic trends.","volume":"64","author":"Hadi","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.09.040","article-title":"Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-a retrospective analysis.","volume":"78","author":"Xia","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.01.002","article-title":"Perioperative management of pyoderma gangrenosum.","volume":"83","author":"Haag","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068211","article-title":"A rapidly progressing, painful ulcer at a surgical wound site.","volume":"376","author":"Rao","year":"2022","journal-title":"BMJ."},{"key":"B69","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1111\/ans.15316","article-title":"Post-surgical pyoderma gangrenosum of the breast: a diagnostic dilemma?","volume":"90","author":"Solis","year":"2020","journal-title":"ANZ J Surg."},{"key":"B70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/01.ASW.0000579692.74662.bb","article-title":"Rare presentation of postsurgical pyoderma gangrenosum presenting as necrotizing soft tissue infection.","volume":"32","author":"Flynn","year":"2019","journal-title":"Adv Skin Wound Care."},{"key":"B71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/TA.0000000000002096","article-title":"Pyoderma gangrenosum misdiagnosis resulting in amputation: a review.","volume":"86","author":"Haag","year":"2019","journal-title":"J Trauma Acute Care Surg."},{"key":"B72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/wound.2020.1160","article-title":"Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and skin grafting, including xenografts: personal experience and comprehensive review on 161 cases.","volume":"9","author":"Eisendle","year":"2020","journal-title":"Adv Wound Care (New Rochelle)."},{"key":"B73","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/wrr.12918","article-title":"The surgical approach to pyoderma gangrenosum: a retrospective monocenter study.","volume":"29","author":"Bingoel","year":"2021","journal-title":"Wound Repair Regen."},{"key":"B74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bjps.2017.08.013","article-title":"Reconstructive microsurgical approach for the treatment of pyoderma gangrenosum.","volume":"71","author":"Schwaiger","year":"2018","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"B75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/wrr.12910","article-title":"The role of negative pressure wound therapy (npwt) on the treatment of pyoderma gangrenosum: a systematic review and personal experience.","volume":"29","author":"Almeida","year":"2021","journal-title":"Wound Repair Regen."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2017.7209","article-title":"Combination of negative pressure wound therapy and systemic steroid therapy in postsurgical pyoderma gangrenosum after reduction mammoplasty; a case of proven efficacy and safety.","volume":"9","author":"Tanini","year":"2017","journal-title":"Dermatol Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/apt.15766","article-title":"Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1134939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:31:50Z","timestamp":1676374310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1134939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":78,"alternative-id":["10.3389\/fmed.2023.1134939"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1134939","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"article-number":"1134939"}}